Dry Powder Inhalers (DPI)

24. March 2017 Abstract   Introduction: Early dry powder inhalers (DPIs) were designed for low drug doses in asthma and...

29. January 2017 Background Inhaled medication is the cornerstone of the pharmacological treatment for patients with asthma and chronic obstructive...

03. January 2017 Abstract Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), is part of first-line therapy for the treatment...

18. November 2016 EXCIPURE - Lactose Solutions for Dry Powder Inhalation -  launched by Armor Pharma  

18. October 2016 Abstract The present study focuses on the development of dry powders for inhalation as adjuvant chemotherapy in...

10. July 2016 Abstract The current work outlines the application of an up-to-date and regulatory-based pharmaceutical quality management method, applied...

  15. April 2015 Our quest for excellence has led us to a sustainable level of product development : a structured...